https://www.zacks.com/stock/news/2275627/m-t-bank-mtb-expands-ncino-partnership-for-ai-credit-solution?cid=CS-ZC-FT-analyst_blog|company_news_-_finance_sector-2275627
May 17, 2024 - M&T Bank (MTB) is integrating a continuous credit monitoring solution by nCino to strengthen its capabilities in order to manage credit risk better.
zc:1877494994861910016
0
https://www.zacks.com/stock/news/2275579/amgen-s-amgn-tarlatamab-receives-fda-approval-for-sclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2275579
May 17, 2024 - Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
zc:3588628673944611843
0
https://seekingalpha.com/article/4693808-wall-street-breakfast-podcast-at-and-t-strikes-deal-with-ast-spacemobile-for-satellite-to-cellphone-service?source=feed_tag_wall_st_breakfast
May 16, 2024 - AT&T goes up against Elon Musk's Starlink with AST SpaceMobile deal. China's NIO changing its global strategy as U.S., EU tariffs loom - report. Peloton hires J.P. Morgan.
0
sa:6476538538524767192
0
https://www.zacks.com/stock/news/2273949/want-better-returns-don-t-ignore-these-2-computer-and-technology-stocks-set-to-beat-earnings?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2273949
May 15, 2024 - Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
zc:-5685862665790740410
0
https://www.zacks.com/stock/news/2272493/w-t-offshore-wti-reports-q1-loss-tops-revenue-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-2272493
May 10, 2024 - W&T (WTI) delivered earnings and revenue surprises of -25% and 1.31%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
zc:7540501309185974582
0
https://www.fool.com/investing/2024/05/10/3-rock-solid-dividend-stocks-ideal-for-retirees/?source=iedfolrf0000001
May 10, 2024 - These are low-risk stocks with high yields.
0
fool:1153363227958024531
0
https://seekingalpha.com/news/4104222-gilead-kite-arcellx-share-phase-3-trial-design-car-t-multiple-myeloma-asset?source=feed_sector_healthcare
May 09, 2024 - Kite and Arcellx will conduct a phase 3 study of their CAR-T multiple myeloma treatment, with preliminary data expected by the end of 2024.
0
sa:-2850960040142258799
0
https://seekingalpha.com/article/4687059-t-bills-gold-and-macro-volatility?source=feed_tag_wall_st_breakfast
Apr 27, 2024 - Amrita Roy and Rob Isbitts are both bullish on gold and T-bills. Inflationary and deflationary tug of war and macro volatility.
0
sa:4937889057427947299
0
https://www.zacks.com/stock/news/2263526/t-rowe-price-trow-q1-earnings-beat-estimates-aum-rises-y-y?cid=CS-ZC-FT-analyst_blog|earnings_article-2263526
Apr 26, 2024 - T. Rowe Price's (TROW) Q1 earnings beat estimates on increased net revenues, an improvement in AUM and a decline in expenses. A rise in cash and cash equivalents will help it continue investing.
zc:5563688798752567667
0
https://www.zacks.com/stock/news/2263203/t-rowe-trow-q1-earnings-how-key-metrics-compare-to-wall-street-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2263203
Apr 26, 2024 - Although the revenue and EPS for T. Rowe (TROW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
zc:2328748303359065055
0